Shares of Cerus Corporation (NASDAQ:CERS) have received a consensus recommendation of “Hold” from the seven analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $7.00.
CERS has been the subject of a number of research reports. ValuEngine lowered shares of Cerus Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. BidaskClub lowered shares of Cerus Corporation from a “hold” rating to a “sell” rating in a research note on Friday, August 25th. Cowen and Company set a $6.00 target price on shares of Cerus Corporation and gave the company a “buy” rating in a research note on Thursday, October 5th. Finally, Zacks Investment Research upgraded shares of Cerus Corporation from a “sell” rating to a “hold” rating in a research note on Monday, October 16th.
TRADEMARK VIOLATION WARNING: This story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/11/05/cerus-corporation-cers-receives-consensus-rating-of-hold-from-brokerages.html.
In other Cerus Corporation news, insider Laurence M. Corash acquired 92,796 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was purchased at an average price of $2.45 per share, with a total value of $227,350.20. Following the transaction, the insider now directly owns 1,375,711 shares in the company, valued at approximately $3,370,491.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 7.40% of the company’s stock.
A number of institutional investors have recently modified their holdings of CERS. First Manhattan Co. boosted its holdings in Cerus Corporation by 31.3% in the 2nd quarter. First Manhattan Co. now owns 42,000 shares of the biotechnology company’s stock worth $105,000 after buying an additional 10,000 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in Cerus Corporation by 59.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 48,377 shares of the biotechnology company’s stock worth $121,000 after buying an additional 18,000 shares during the period. Russell Investments Group Ltd. bought a new position in Cerus Corporation in the 1st quarter worth $137,000. Voya Investment Management LLC boosted its holdings in Cerus Corporation by 22.0% in the 2nd quarter. Voya Investment Management LLC now owns 58,633 shares of the biotechnology company’s stock worth $147,000 after buying an additional 10,570 shares during the period. Finally, Ardsley Advisory Partners bought a new position in Cerus Corporation in the 2nd quarter worth $200,000. 58.38% of the stock is owned by institutional investors.
Shares of Cerus Corporation (NASDAQ CERS) traded up $0.64 on Friday, reaching $3.52. 3,611,018 shares of the company’s stock were exchanged, compared to its average volume of 774,446. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.46 and a current ratio of 2.94.
Cerus Corporation (NASDAQ:CERS) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. The business had revenue of $10.80 million during the quarter, compared to analyst estimates of $11.95 million. Cerus Corporation had a negative net margin of 159.35% and a negative return on equity of 135.25%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.14) EPS. equities research analysts predict that Cerus Corporation will post -0.64 earnings per share for the current year.
About Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
What are top analysts saying about Cerus Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cerus Corporation and related companies.